- Company Details
SBIR Phase I: Development and Validation of an In Vitro Diagnostic of HDL Cholesterol Efflux and Coronary Artery Disease RiskAmount: $150,000.00
This Small Business Innovation Research (SBIR) Phase I project will develop a new approach to accurately predict coronary artery disease (CAD) risk. Because high-density-lipoprotein (HDL) protects fro ...SBIRPhase I2013National Science Foundation
Accent Assays, Inc.
Sacramento, CA, 95811-3107
|# of Employees:||4|
|Socially and Economically Disadvantaged:||N|